


Clinical development and global collaboration of NS101: A novel monoclonal antibody therapeutic for sensorineural hearing loss through synaptic restoration

Neuracle Science. Co., Ltd.



OTHERS	Phase 2
Product Type	Monoclonal Antibody (anti-FAM19A5 antibody, functioning synapse restoration)
Indication	Sudden Sensorineural Hearing Loss (SSNHL)
Target	FAM19A5 (functioning synapse elimination)
MoA(Mechanism of Action)	Functional recovery by synapse restoration via anti-FAM19A5 antibody
Competitiveness	<ul style="list-style-type: none"> ✓ First-in-class MOA with extensibility potential: versatile diseases (i.e. sensorineural diseases, neurodegenerative diseases, neurological diseases & neuronal disabilities) can be treated if related with accumulated synaptopathy ✓ Therapeutic potential: The amino acid sequence of FAM19A5 is 100% identical across vertebrates, including humans ➡ well conserved, very important protein thru evolution ✓ Safety potential by disinhibiting MOA: not more than normal
Development Stage	Clinical Trial Phase 1b/2a
Route of Administration	Intravenous